Clinic for Cardiovascular Surgery, German Heart Center Munich, Munich, Germany.
JACC Cardiovasc Interv. 2010 May;3(5):524-30. doi: 10.1016/j.jcin.2010.01.017.
The aim of this study was to identify risk factors for new-onset atrioventricular (AV) block requiring pacemaker (PM) implantation after transcatheter aortic valve implantation (TAVI).
High-grade AV block and consecutive PM implantation are frequent complications following TAVI.
For logistic regression analysis, we included 159 patients (mean age: 81 +/- 6 years, EuroSCORE: 22 +/- 13%) who underwent TAVI (n = 116 transfemoral, n = 4 via subclavian artery, n = 37 transapical, n = 2 transaortic) between June 2007 and January 2009 and who had no previously implanted PM.
Thirty-five patients (22%) developed new-onset post-operative AV block with the need of PM implantation. Logistic regression revealed a 2-fold increased risk for new-onset AV block in patients in whom a large valve is implanted in a small annulus (32% pacemaker implantations, odds ratio [OR]: 2.378, p = NS), a 4-fold increased risk with the implantation of the CoreValve (Medtronic, Minneapolis, Minnesota) versus the Edwards Sapien valve (Edwards Lifesciences, Irvine, California) (27% pacemaker implantations, OR: 3.781, p = NS), and a 5-fold increased risk for patients who exhibit an AV block episode instantly during the implantation procedure (49% pacemaker implantations, OR: 4.819, p = 0.001). Pre-existing ECG alterations were not identified as risk factors for AV block after transcatheter aortic valve implantation.
We assume that conduction tissue impairment is provoked by mechanical compression with large prostheses in smaller annuli or in the larger area of the CoreValve covering the outflow tract and may appear instantly during the implantation procedure. Continuous post-operative electrocardiogram monitoring should be performed for at least 3 days in all patients after TAVI procedures and until discharge in patients with increased risk for this complication.
本研究旨在确定经导管主动脉瓣置换术(TAVI)后新发房室(AV)传导阻滞并需植入起搏器(PM)的危险因素。
TAVI 后,高度房室传导阻滞和随后的 PM 植入是常见的并发症。
我们纳入了 159 名患者(平均年龄 81±6 岁,EuroSCORE:22±13%)进行逻辑回归分析,这些患者于 2007 年 6 月至 2009 年 1 月期间接受了 TAVI(经股动脉 n=116,经锁骨下动脉 n=4,经心尖 n=37,经主动脉 n=2),且均未植入过 PM。
35 名患者(22%)新发术后 AV 传导阻滞,需要植入 PM。逻辑回归显示,在植入小瓣环的大瓣膜(32%需植入 PM,优势比[OR]:2.378,p=NS)、植入 CoreValve(美敦力,明尼苏达州明尼阿波利斯)而非 Edwards Sapien 瓣膜(爱德华兹生命科学公司,加利福尼亚州欧文)(27%需植入 PM,OR:3.781,p=NS)的患者中,新发 AV 传导阻滞的风险增加了 2 倍,在植入过程中即刻出现 AV 阻滞的患者中,风险增加了 4 倍(49%需植入 PM,OR:4.819,p=0.001)。
我们认为,在较小瓣环或 CoreValve 覆盖流出道的较大区域中,较大的瓣膜可能会导致机械压迫,从而引起传导组织损伤,且可能在植入过程中即刻出现。所有 TAVI 术后患者应至少连续监测 3 天心电图,对于有此并发症风险增加的患者,应监测至出院。